Conversely, adding 1.2 mL instead of 1.0 mL dilutes to 8.33 mg/mL, and every dose is about 17% weaker than planned
Staresinic M, et al
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
It is sold as a research reagent (research chemical, not for human use) by suppliers operating in the gray-market peptide space
Pre-filled compounded pens, if your pharmacy offers them, may have slightly different timelinesyour pharmacist will provide specific dates with your order
In a Phase III study of 187 PAH patients comparing Opsynvi to macitentan and tadalafil monotherapy, J&Js drug was superior in n reducing pulmonary vascular resistance
